JCNN News Summaries - Japan Corporate News Network - Eisai Announces Expanded Manufacturing Facility Completed at Misato
Eisai Co., Ltd. (TSE: 4523) has announced the dedication of a new formulation facility, N1 Building, at the Misato Plant in Saitama Prefecture.
The N1 Building will enable the company to expand the production capacity for the proton pump inhibitor, ACIPHEX / PARIET (rabeprazole sodium), thereby meeting increasing worldwide demand while reducing the production cost.
In addition, the facility has incorporated packaging operations previously performed in the older building and was also designed to accommodate regulatory agencies’ guidelines for Good Manufacturing Practices (GMPs), which have become increasingly stringent for all pharmaceutical manufacturers. The N1 Building is designed for maximum operational safety, protecting workers from any potential chemical hazard, as well as taking resource conservation into consideration by introducing a variety of cutting-edge energy-efficient equipment.
Related Results
AciphexAciphexAciphex approvalAciphex approvedEisai, Janssen Revamp Aciphex Packaging
PARIET was first launched in Japan in 1977, and it was launched under the tradename ACIPHEX in the United States in 1999. Currently the product has been launched in approximately 72 countries worldwide.
c 2005 Japan Corporate News Network. All rights reserved.
Provided by ProQuest Information and Learning Company. All rights Reserved.
